News | Heart Failure | September 16, 2015

Cost-effectiveness of CardioMEMS and Entresto for Heart Failure Management Reviewed

Report suggests price benchmarks to maximize both costs and improved outcomes in the long term

ICER, CardioMEMS, Entresto, congestive heart failure, cost-effectiveness

CardioMEMS image courtesy of St. Jude Medical.

September 16, 2015 — The Institute for Clinical and Economic Review (ICER) has released a new report offering a comprehensive review of currently available evidence on two new interventions as potential advances in the care of congestive heart failure (CHF) patients. The report is titled CardioMEMS HF System (St. Jude Medical) and Sacubitril/Valsartan (Entresto, Novartis) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks.

The first system discussed, known as CardioMEMS, monitors increases in pulmonary artery pressure (a key indicator of worsening CHF) , and the second is the medication sacubitril/valsartan (Entresto) to treat CHF. The ICER report provides analyses of long-term cost-effectiveness and the potential budget impact of these new interventions. In addition, the results of these analyses are used to calculate a value-based price benchmark for each intervention.  These price benchmarks reflect estimates of how much better the interventions are at improving patient outcomes, tempered by thresholds at which additional new costs would contribute to growth in healthcare costs exceeding growth in the overall national economy.

CHF represents a major public health concern, currently affecting nearly 6 million individuals in the United States.  Growth in per capita medical spending and aging of the population are expected to contribute to substantial increases in the direct medical costs of treating CHF, with annual costs totaling nearly $80 billion by 2030.

"Figuring out the effectiveness and value of new drugs and devices is not merely an academic exercise," noted Steven D. Pearson, M.D., MSc, founder and president of ICER.  "The headlines are full of stories about rising healthcare costs and their impact on patients, families, and the budgets of states and the federal government.  A clear-eyed view of the evidence is critical to all members of the healthcare community as we try to figure out what should be used, which patients benefit most and at what price innovative treatments represent a reasonable value."

ICER's analysis concludes that there is moderate certainty that Entresto provides a small to substantial net health benefit compared to the current standard of care in patients with CHF. Entresto increases the average length of life for patients and also decreases the number of hospitalizations for CHF. At the list price of $4,560 per year, Entresto does not save money over the long term but its added costs are well-aligned with the degree of benefit it brings to patients. This means Entresto can be judged "cost-effective" in the long term according to commonly accepted cost-effectiveness thresholds.

However, ICER's analysis predicts that nearly 2 million patients could be prescribed Entresto over the first five years, creating a total budget impact so high that excessive cost burdens would be placed on the overall healthcare system. In order to keep healthcare cost growth in line with growth in the national economy, ICER's value-based price benchmark for Entresto is $3,779 annually, a 17 percent discount off the list price.  Private insurers and Medicaid programs are frequently able to achieve discounts at this level.

Regarding the CardioMEMS HF System, the ICER analysis concludes that the current evidence is "insufficient" to be able to determine that it improves overall patient outcomes. If the device is used, however, at a list price of $17,750, it would also exceed the threshold for potential budget impact that indicates an excessive cost to the overall healthcare system. As Pearson noted, "When estimated patterns of CardioMEMS uptake are considered, our value-based price benchmark for CardioMEMS comes in at $7,622, a nearly 60 percent discount off the current list price."

The draft report, as well as accompanying draft voting questions, will be open to public comment until Sept. 25, 2015.

For more information: www.icer-review.org

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Overlay Init